發(fā)布時間：2018-10-04 20:22

【摘要】：正內(nèi)皮素受體拮抗劑是慢性腎臟病及難治性高血壓新的潛在治療藥物,但可導(dǎo)致鈉水潴留。動物研究發(fā)現(xiàn),此副作用是由于腎小管內(nèi)皮素B受體阻滯所致。該研究的目的是通過給予亞升壓劑量的內(nèi)皮素1前體,即大內(nèi)皮素1,探討人腎小管內(nèi)皮素信號在鹽轉(zhuǎn)運中的作用。在10個健康志愿者中進(jìn)行一項二期隨機(jī)、雙盲、安慰劑對照交叉試驗。限鹽后靜脈給予研究對
[Abstract]:Positive endothelin receptor antagonist is a new potential therapy for chronic kidney disease and refractory hypertension, but it can lead to sodium retention. Animal studies have found that this side effect is due to tubular endothelin B receptor block. The aim of this study was to investigate the role of human renal tubular endothelin signal in salt transport by subpressor dose of endothelin 1 precursor, large endothelin 1. A two-phase randomized, double blind, placebo-controlled cross-control trial was conducted in 10 healthy volunteers. Study of intravenous administration after salt limitation
【分類號】：R969

【相似文獻(xiàn)】

相關(guān)期刊論文 前8條

1 唐德q，

本文編號：2251753